Trial Profile
A phase III study of oral Nadolol (INV102) as a treatment for patients with COPD who cannot quit cigarette smoking.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 08 Feb 2017
Price :
$35
*
At a glance
- Drugs Nadolol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 08 Feb 2017 New trial record